Literature DB >> 26823908

Multiple myeloma developing during long-term clinical course of refractory immune thrombocytopenic purpura: a case report and review of literature.

Han Yao1, Xi Zhang1, Jia Liu1, Lidan Zhu1, Guo Chen1, Sha Wu1, Lei Gao1.   

Abstract

Immune thrombocytopenia (ITP) is an acquired, immune-mediated disease that is characterized by increased destruction of platelets by autoantibodies. Although the onset of the disease and clinical course are highly variable, the disease typically has a benign course. ITP associated with multiple myeloma (MM) has been rarely reported; it is even rarer for MM to develop during a long-term ITP (almost 20 years). Here, we first report on a case with a 20-year long clinical course of refractory ITP followed by newly diagnosed MM.

Entities:  

Keywords:  Immune thrombocytopenic purpura; bortezomib; immunosuppression; multiple myeloma

Mesh:

Year:  2015        PMID: 26823908      PMCID: PMC4713694     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  10 in total

1.  Long-term outcomes in adults with chronic ITP after splenectomy failure.

Authors:  Robert McMillan; Carol Durette
Journal:  Blood       Date:  2004-04-20       Impact factor: 22.113

Review 2.  AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.

Authors:  Matthew C Cheung; Liron Pantanowitz; Bruce J Dezube
Journal:  Oncologist       Date:  2005 Jun-Jul

Review 3.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

Review 4.  Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.

Authors:  Giada Bianchi; Kenneth C Anderson
Journal:  CA Cancer J Clin       Date:  2014-09-29       Impact factor: 508.702

5.  Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Authors:  Sagar Lonial; Edmund K Waller; Paul G Richardson; Sundar Jagannath; Robert Z Orlowski; Cynthia R Giver; David L Jaye; Dixil Francis; Sara Giusti; Claire Torre; Bart Barlogie; James R Berenson; Seema Singhal; David P Schenkein; Dixie-Lee W Esseltine; Jessica Anderson; Hugh Xiao; Leonard T Heffner; Kenneth C Anderson
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

6.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

7.  Multiple myeloma and immune thrombocytopenia.

Authors:  V Gupta; U M Hegde; R Parameswaran; A C Newland
Journal:  Clin Lab Haematol       Date:  2000-08

8.  A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.

Authors:  Hai Zhou; Miao Xu; Ping Qin; Hai-yan Zhang; Cheng-lu Yuan; Hong-guo Zhao; Zhong-guang Cui; Yue-sheng Meng; Lei Wang; Fang Zhou; Xin Wang; Da-qi Li; Ke-hong Bi; Chuan-sheng Zhu; Cheng-shan Guo; Xiao-xia Chu; Qing-chao Wu; Xin-guang Liu; Xiao-yuan Dong; Jie Li; Jun Peng; Ming Hou
Journal:  Blood       Date:  2015-01-09       Impact factor: 22.113

9.  Spectrum of AIDS-associated malignant disorders.

Authors:  J J Goedert; T R Coté; P Virgo; S M Scoppa; D W Kingma; M H Gail; E S Jaffe; R J Biggar
Journal:  Lancet       Date:  1998-06-20       Impact factor: 79.321

Review 10.  Low dose cepharanthine ameliorates immune thrombocytopenic purpura associated with multiple myeloma.

Authors:  Rie Tabata; Chiharu Tabata; Ayako Tazoh; Tomoko Nagai
Journal:  Int Immunopharmacol       Date:  2012-05-03       Impact factor: 4.932

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.